KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.

Brian S Kim, Margarida Gonçalo, Tsukasa Ugajin, Xing-Hua Gao, Amy H Praestgaard, Melanie Makhija, Joseph Zahn, Ashish Bansal, Simmi Wiggins

Am J Clin Dermatol 27(1) 167-180

PMID41219577
PMCIDPMC12860806
DOI10.1007/s40257-025-00993-1
发表日期2025-11-11
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by intensely pruritic papulonodular lesions. Patients with PN frequently experience comorbid atopic conditions. Dupilumab is the first approved therapy for PN, but the efficacy of dupilumab in patients with PN with or without atopic comorbidities has not been investigated. OBJECTIVE: We aimed to assess the efficacy and safety of dupilumab in patients with PN with or without a history of atopic comorbidities. METHODS: Randomized, double-blind, parallel-group, placebo-controlled, 24-week, phase III trials LIBERTY-PN PRIME and PRIME2 were conducted independently in 16 countries in North and South America, Europe, and Asia. Patients were randomized 1:1 to dupilumab 300 mg every 2 weeks or matched placebo. In this pre-specified subgroup analysis of pooled data, adults with moderate-to-severe PN, inadequately controlled by topical prescription therapies, were stratified according to the presence or absence of atopic comorbidity history. Investigators assessed itch (Worst Itch Numeric Rating Scale), skin lesions (Investigator's Global Assessment for PN Stage), and patient-reported quality of life (evaluated using the Dermatology Life Quality Index, Skin Pain Numeric Rating Scale, Hospital Anxiety and Depression Scale, and a Sleep Numeric Rating Scale). RESULTS: Three hundred and eleven patients were randomized to dupilumab (N = 153; atopic/non-atopic n = 67/86) or placebo (N = 158; atopic/non-atopic n = 68/90). At week 24 in both the atopic and non-atopic subgroups, significantly more patients achieved clinically meaningful improvements with dupilumab treatment compared with placebo in itch (atopic: 58.2% vs 20.6%; P < 0.0001; non-atopic: 59.3% vs 17.8%; P < 0.0001), clear/almost clear skin (atopic: 52.2% vs 16.2%; P < 0.0001; non-atopic: 41.9% vs 17.8%; P = 0.0005), and concomitant itch and skin lesion improvements (atopic: 37.3% vs 7.4%; P = 0.0057; non-atopic 33.7% vs 10.0%; P = 0.007). Patients showed significant improvements in skin pain, Dermatology Life Quality Index, Hospital Anxiety and Depression Scale, and sleep, with dupilumab treatment compared with placebo, regardless of atopic history. Safety was generally consistent with the known dupilumab safety profile. CONCLUSIONS: Dupilumab significantly improved disease signs, symptoms, and health-related quality of life with similar onset time and response magnitude compared with placebo in adult patients with PN, irrespective of the presence or absence of atopic comorbidities. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT04183335 and NCT04202679.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Efficacy of dupilumab on itch and skin lesions at week 12 and week 24 in patients with prurigo nodularis by atopic versus non-atopic subgroup. a Worst Itch Numeric Rating Scale (WI-NRS) improvement ≥ 4, b Investigator’s Global Assessment for PN Stage (IGA PN-S) score of 0 or 1, and c WI-NRS improvement ≥ 4 and Investigator’s Global Assessment (IGA) score of 0 or 1. q2w every 2 weeks
非 KM Figure
Fig. 2Efficacy on other patient-reported outcomes at week 24 by atopic versus non-atopic subgroup. Least squares mean percent change (standard error). * P < 0.05 vs placebo; ** P < 0.001 versus placebo; *** P < 0.0001 versus placebo. Scales: Worst Itch Numeric Rating Scale (WI-NRS): 0, “no itch” to 10, “worst imaginable itch”; Skin Pain-Numeric Rating Scale (Skin Pain-NRS): 0, “no pain” to 10, “worst imaginable pain”; Dermatology Life Quality Index (DLQI): 0, “no effect on patient’s life” to 30, “extremely large effect on patient’s life”; Sleep-Numeric Rating Scale (Sleep-NRS): 0, “worst possible sleep” to 10, “best possible sleep”; Hospital Anxiety and Depression Scale (HADS): two subscales, one for anxiety [0–21] and one for depression [0–21]: 0, “normal or no anxiety/depression” to 21, “severe anxiety/depression”
非 KM Figure